Metastasis-Directed Therapy (MDT)
Targeting and ablating limited metastatic disease sites (1 to 5 spots) with SBRT to delay systemic progression and prolong survival.
Aggressive local ablation of limited metastatic sites to change the trajectory of metastatic cancer.
The 'oligometastatic' state represents a crucial window where cancer has spread to a limited number of sites (typically 1 to 5 lesions in the bones, lungs, liver, or lymph nodes) rather than widespread dissemination.
Clinical trials (such as SABR-COMET and ORIOLE) have proven that treating all visible metastatic lesions with high-dose SBRT significantly prolongs progression-free survival, delays the need for aggressive chemotherapy or hormone therapy, and can achieve durable remission.
Advanced imaging with 68Ga-PSMA PET/CT (for prostate cancer) and 18F-FDG PET/CT allows precise identification and ablation of metastatic targets in a non-invasive manner.
Key Clinical Considerations in Your Consultation
Every recommendation is customized according to staging scans, pathology markers, and patient priorities.
Oligometastatic and oligoprogressive disease staging with PET/CT and MRI
SBRT ablation for solitary and limited bone, lung, liver, and nodal metastases
Delaying initiation or escalation of systemic chemotherapy and hormone therapy
Synergistic combination of local SBRT with modern immunotherapy and targeted agents
Sparing quality of life by avoiding invasive surgical metastasectomy
Multidisciplinary case review for complex multi-organ metastatic presentations
Discuss Metastasis-Directed Therapy (MDT)
Bring biopsy reports, recent PET/CT or MRI scans, and operative summaries for a comprehensive consultation.